Table 1.
Clinical characteristics of the study cohort
| N | 131 |
| Age, years, median (IQR) | 63 (55–69) |
| Sex | |
| Male | 72 (55%) |
| Female | 59 (45%) |
| Race | |
| Non-Hispanic white | 105 (80%) |
| Hispanic | 23 (18%) |
| Black | 3 (2%) |
| Type of malignancy | |
| Solid malignancies | 106 (81%) |
| Breast | 27 |
| Urological | 20 |
| Gynecological | 3 |
| Skin cancersa | 7 |
| Thoracic malignancy | 18 |
| Gastrointestinal | 16 |
| Head and neck cancer | 3 |
| Brain | 8 |
| Connective tissue | 4 |
| Hematological malignancies | 25 (19%) |
| Acute lymphoblastic leukemia | 1 |
| Chronic myeloid leukemia | 1 |
| Chronic lymphocytic leukemia | 1 |
| Diffuse large B cell lymphoma | 6 |
| Follicular lymphoma | 2 |
| MALT lymphoma | 2 |
| T cell lymphoma/mycosis fungoides | 2 |
| Hodgkin's lymphoma | 4 |
| Polycythemia vera | 1 |
| Myeloma | 5 |
| Type of anti-cancer treatmentb(within 6 months before vaccination) | |
| Clinical surveillance | 49 (37%) |
| Cytotoxic chemotherapy | 30 (23%) |
| Immunotherapy | 14 (11%) |
| Endocrine therapy | 19 (15%) |
| Anti-CD-20 antibody | 4 (3%) |
| Anti-CD-38 antibody | 1 (1%) |
| Anti-HER antibody | 2 (2%) |
| Anti-VEGF antibody | 6 (5%) |
| RANKL antibody | 4 (3%) |
| Kinase inhibitor | 15 (11%) |
| Unknownc | 1 (1%) |
| SARS-CoV-2 vaccine | |
| BNT162b2 | 38 (29%) |
| mRNA-1273 | 93 (71%) |
| Days between first vaccine dose and final outcome measurement, median (range) | 50 (49–55) |
| Days between second vaccine dose and final outcome measurement, median (range) | 24 (22–24) |
a
Six melanoma, one Merkel cell.
b
Twelve patients received more than one anti-cancer treatment.
c
Patient enrolled in a double-blinded placebo-controlled trial.